Safety
dyspepsia, deaths, Treatment-emergent adverse, anemia
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME, ANEMIA
Treatment-emergent AEs (TEAEs) are summarized in Table Treatment-emergent adverse eventsData are Twelve (12.0%) of 100 patients had dose reductions of pyrotinib due to AEs, and 37 (37.0%) had dose reductions of capecitabine. Four (4.0%) patients discontinued capecitabine due to increased blood bilirubin, anemia, dyspepsia, and palmar-plantar erythrodysesthesia syndrome, respectively. No AEs leading to discontinuation of pyrotinib occurred. No treatment-related deaths occurred.